{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:36:27Z","timestamp":1790660187705,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK112293"],"award-info":[{"award-number":["DK112293"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK112293"],"award-info":[{"award-number":["DK112293"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK112293"],"award-info":[{"award-number":["DK112293"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK112293"],"award-info":[{"award-number":["DK112293"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-024-02317-4","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T01:01:41Z","timestamp":1729126901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["MASLD in persons with HIV is associated with high cardiometabolic risk as evidenced by altered advanced lipoprotein profiles and targeted metabolomics"],"prefix":"10.1186","volume":"23","author":[{"given":"Kung-Hung","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Vilar-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E.","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margery A.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan E.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Gawrieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"2317_CR1","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S2352-3018(20)30036-9","volume":"7","author":"K So-Armah","year":"2020","unstructured":"So-Armah K, Benjamin LA, Bloomfield GS, Feinstein MJ, Hsue P, Njuguna B, Freiberg MS. HIV and cardiovascular disease. Lancet HIV. 2020;7:e279\u201393.","journal-title":"Lancet HIV"},{"key":"2317_CR2","doi-asserted-by":"publisher","first-page":"e000722","DOI":"10.1136\/openhrt-2017-000722","volume":"5","author":"W Lieb","year":"2018","unstructured":"Lieb W, Enserro DM, Larson MG, Vasan RS. Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community. Open Heart. 2018;5:e000722.","journal-title":"Open Heart"},{"key":"2317_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jacl.2018.01.002","volume":"12","author":"JD Otvos","year":"2018","unstructured":"Otvos JD, Guyton JR, Connelly MA, Akapame S, Bittner V, Kopecky SL, Lacy M, et al. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: a post hoc analysis of the AIM-HIGH trial. J Clin Lipidol. 2018;12:348\u201355. e342.","journal-title":"J Clin Lipidol"},{"key":"2317_CR4","doi-asserted-by":"publisher","first-page":"e021995","DOI":"10.1161\/JAHA.121.021995","volume":"10","author":"E Tikkanen","year":"2021","unstructured":"Tikkanen E, Jagerroos V, Holmes MV, Sattar N, Ala-Korpela M, Jousilahti P, Lundqvist A, et al. Metabolic Biomarker Discovery for risk of Peripheral Artery Disease compared with coronary artery disease: lipoprotein and metabolite profiling of 31 657 individuals from 5 prospective cohorts. J Am Heart Assoc. 2021;10:e021995.","journal-title":"J Am Heart Assoc"},{"key":"2317_CR5","doi-asserted-by":"crossref","unstructured":"Quesada JA, Bertomeu-Gonzalez V, Orozco-Beltran D, Cordero A, Gil-Guillen VF, Lopez-Pineda A, Nouni-Garcia R et al. The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: a systematic review and meta-analysis. Clin Investig Arterioscler 2022.","DOI":"10.1016\/j.arteri.2022.11.001"},{"key":"2317_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1089\/met.2014.0050","volume":"12","author":"I Shalaurova","year":"2014","unstructured":"Shalaurova I, Connelly MA, Garvey WT, Otvos JD. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab Syndr Relat Disord. 2014;12:422\u20139.","journal-title":"Metab Syndr Relat Disord"},{"key":"2317_CR7","doi-asserted-by":"crossref","unstructured":"Flores-Guerrero JL, Gruppen EG, Connelly MA, Shalaurova I, Otvos JD, Garcia E, Bakker SJL et al. A newly developed diabetes risk index, based on Lipoprotein subfractions and branched chain amino acids, is Associated with Incident Type 2 diabetes Mellitus in the PREVEND Cohort. J Clin Med 2020;9.","DOI":"10.3390\/jcm9092781"},{"key":"2317_CR8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.atherosclerosis.2009.05.001","volume":"207","author":"DA Duprez","year":"2009","unstructured":"Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, Neuhaus J, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis. 2009;207:524\u20139.","journal-title":"Atherosclerosis"},{"key":"2317_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/QAI.0b013e31824476e1","volume":"60","author":"HC Bucher","year":"2012","unstructured":"Bucher HC, Richter W, Glass TR, Magenta L, Wang Q, Cavassini M, Vernazza P, et al. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2012;60:135\u201342.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2317_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347.","journal-title":"Hepatology"},{"key":"2317_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/HEP.0000000000000313","volume":"78","author":"S Gawrieh","year":"2023","unstructured":"Gawrieh S, Lake JE, Debroy P, Sjoquist JA, Robison M, Tann M, Akisik F, et al. Burden of fatty liver and hepatic fibrosis in persons with HIV: a diverse cross-sectional US multicenter study. Hepatology. 2023;78:578\u201391.","journal-title":"Hepatology"},{"key":"2317_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cgh.2022.03.048","volume":"21","author":"M Lemoine","year":"2023","unstructured":"Lemoine M, Assoumou L, Girard PM, Valantin MA, Katlama C, De Wit S, Campa P, et al. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European Multicenter prospective study. Clin Gastroenterol Hepatol. 2023;21:713\u201322. e713.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2317_CR13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835.","journal-title":"Hepatology"},{"key":"2317_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/hep4.1822","volume":"6","author":"F Luo","year":"2022","unstructured":"Luo F, Oldoni F, Das A. TM6SF2: a Novel Genetic Player in nonalcoholic fatty liver and Cardiovascular Disease. Hepatol Commun. 2022;6:448\u201360.","journal-title":"Hepatol Commun"},{"key":"2317_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MOG.0000000000000927","volume":"39","author":"V Ajmera","year":"2023","unstructured":"Ajmera V, Loomba R. Advances in the genetics of nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2023;39:150\u20135.","journal-title":"Curr Opin Gastroenterol"},{"key":"2317_CR16","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/hep.29273","volume":"66","author":"S BasuRay","year":"2017","unstructured":"BasuRay S, Smagris E, Cohen JC, Hobbs HH. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology. 2017;66:1111\u201324.","journal-title":"Hepatology"},{"key":"2317_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jcmgh.2021.12.008","volume":"13","author":"F Luo","year":"2022","unstructured":"Luo F, Smagris E, Martin SA, Vale G, McDonald JG, Fletcher JA, Burgess SC, et al. Hepatic TM6SF2 is required for Lipidation of VLDL in a Pre-golgi Compartment in mice and rats. Cell Mol Gastroenterol Hepatol. 2022;13:879\u201399.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2317_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11904-018-0392-1","volume":"15","author":"S Soti","year":"2018","unstructured":"Soti S, Corey KE, Lake JE, Erlandson KM. NAFLD and HIV: do sex, race, and ethnicity explain HIV-Related risk? Curr HIV\/AIDS Rep. 2018;15:212\u201322.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2317_CR19","doi-asserted-by":"publisher","first-page":"905126","DOI":"10.3389\/fphar.2022.905126","volume":"13","author":"C Busca","year":"2022","unstructured":"Busca C, Arias P, Sanchez-Conde M, Rico M, Montejano R, Martin-Carbonero L, Valencia E, et al. Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD. Front Pharmacol. 2022;13:905126.","journal-title":"Front Pharmacol"},{"key":"2317_CR20","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.3748\/wjg.v22.i38.8509","volume":"22","author":"C Sagnelli","year":"2016","unstructured":"Sagnelli C, Merli M, Uberti-Foppa C, Hasson H, Grandone A, Cirillo G, Salpietro S, et al. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency\/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. World J Gastroenterol. 2016;22:8509\u201318.","journal-title":"World J Gastroenterol"},{"key":"2317_CR21","doi-asserted-by":"crossref","unstructured":"Krishnan A, Sims OT, Surapaneni PK, Woreta TA, Alqahtani SA. Risk of adverse cardiovascular outcomes among persons living with HIV and nonalcoholic fatty liver disease: a multicenter matched cohort study. AIDS; 2023.","DOI":"10.1097\/QAD.0000000000003537"},{"key":"2317_CR22","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, Cohen DE, et al. Nonalcoholic fatty liver Disease and Cardiovascular Risk: A Scientific Statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e168\u201385.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2317_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jacl.2017.02.001","volume":"11","author":"AJ Amor","year":"2017","unstructured":"Amor AJ, Pinyol M, Sola E, Catalan M, Cofan M, Herreras Z, Amigo N, et al. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: a focus on atherogenic dyslipidemia. J Clin Lipidol. 2017;11:551\u201361. e557.","journal-title":"J Clin Lipidol"},{"key":"2317_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","volume":"13","author":"MS Siddiqui","year":"2015","unstructured":"Siddiqui MS, Fuchs M, Idowu MO, Luketic VA, Boyett S, Sargeant C, Stravitz RT, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13:1000\u20138. e1003.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2317_CR25","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/oby.23687","volume":"31","author":"L Gnatiuc Friedrichs","year":"2023","unstructured":"Gnatiuc Friedrichs L, Trichia E, Aguilar-Ramirez D, Preiss D. Metabolic profiling of MRI-measured liver fat in the UK Biobank. Obes (Silver Spring). 2023;31:1121\u201332.","journal-title":"Obes (Silver Spring)"},{"key":"2317_CR26","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.cgh.2020.09.039","volume":"19","author":"S Patel","year":"2021","unstructured":"Patel S, Siddiqui MB, Roman JH, Zhang E, Lee E, Shen S, Faridnia M, et al. Association between Lipoprotein Particles and atherosclerotic events in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2021;19:2202\u20134.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2317_CR27","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/hiv.13274","volume":"23","author":"A Cervo","year":"2022","unstructured":"Cervo A, Sebastiani G, Milic J, Krahn T, Mazzola S, Petta S, Cascio A, et al. Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV. HIV Med. 2022;23:911\u201321.","journal-title":"HIV Med"},{"key":"2317_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1530-0277.2003.tb02723.x","volume":"27","author":"JR Knight","year":"2003","unstructured":"Knight JR, Sherritt L, Harris SK, Gates EC, Chang G. Validity of brief alcohol screening tests among adolescents: a comparison of the AUDIT, POSIT, CAGE, and CRAFFT. Alcohol Clin Exp Res. 2003;27:67\u201373.","journal-title":"Alcohol Clin Exp Res"},{"key":"2317_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s11606-008-0594-0","volume":"23","author":"D Frank","year":"2008","unstructured":"Frank D, DeBenedetti AF, Volk RJ, Williams EC, Kivlahan DR, Bradley KA. Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race\/ethnic groups. J Gen Intern Med. 2008;23:781\u20137.","journal-title":"J Gen Intern Med"},{"key":"2317_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","volume":"26","author":"EJ Jeyarajah","year":"2006","unstructured":"Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847\u201370.","journal-title":"Clin Lab Med"},{"key":"2317_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clinbiochem.2014.07.015","volume":"47","author":"SP Matyus","year":"2014","unstructured":"Matyus SP, Braun PJ, Wolak-Dinsmore J, Jeyarajah EJ, Shalaurova I, Xu Y, Warner SM, et al. NMR measurement of LDL particle number using the Vantera Clinical Analyzer. Clin Biochem. 2014;47:203\u201310.","journal-title":"Clin Biochem"},{"key":"2317_CR32","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1373\/clinchem.2014.232918","volume":"61","author":"JD Otvos","year":"2015","unstructured":"Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, Tracy RP. GlycA: a Composite Nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61:714\u201323.","journal-title":"Clin Chem"},{"key":"2317_CR33","doi-asserted-by":"publisher","first-page":"101261","DOI":"10.1016\/j.eclinm.2021.101261","volume":"43","author":"KM Huffman","year":"2022","unstructured":"Huffman KM, Parker DC, Bhapkar M, Racette SB, Martin CK, Redman LM, Das SK, et al. Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: distinct influences of BMI and sex from CALERIE a multicentre, phase 2, randomised controlled trial. EClinicalMedicine. 2022;43:101261.","journal-title":"EClinicalMedicine"},{"key":"2317_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12944-020-01424-2","volume":"19","author":"E Garcia","year":"2020","unstructured":"Garcia E, Bennett DW, Connelly MA, Jeyarajah EJ, Warf FC, Shalaurova I, Matyus SP, et al. The extended lipid panel assay: a clinically-deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and Apolipoprotein B. Lipids Health Dis. 2020;19:247.","journal-title":"Lipids Health Dis"},{"key":"2317_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.clinbiochem.2018.02.001","volume":"54","author":"J Wolak-Dinsmore","year":"2018","unstructured":"Wolak-Dinsmore J, Gruppen EG, Shalaurova I, Matyus SP, Grant RP, Gegen R, Bakker SJL, et al. A novel NMR-based assay to measure circulating concentrations of branched-chain amino acids: Elevation in subjects with type 2 diabetes mellitus and association with carotid intima media thickness. Clin Biochem. 2018;54:92\u20139.","journal-title":"Clin Biochem"},{"key":"2317_CR36","doi-asserted-by":"crossref","unstructured":"Garcia E, Shalaurova I, Matyus SP, Oskardmay DN, Otvos JD, Dullaart RPF, Connelly MA. Ketone Bodies Are Mildly Elevated in subjects with type 2 diabetes Mellitus and are inversely Associated with insulin resistance as measured by the lipoprotein insulin Resistance Index. J Clin Med 2020;9.","DOI":"10.3390\/jcm9020321"},{"key":"2317_CR37","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1016\/S2666-7568(23)00001-6","volume":"4","author":"JD Otvos","year":"2023","unstructured":"Otvos JD, Shalaurova I, May HT, Muhlestein JB, Wilkins JT, McGarrah RW 3rd, Kraus WE. Multimarkers of metabolic malnutrition and inflammation and their association with mortality risk in cardiac catheterisation patients: a prospective, longitudinal, observational, cohort study. Lancet Healthy Longev. 2023;4:e72\u201382.","journal-title":"Lancet Healthy Longev"},{"key":"2317_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, Neuschwander-Tetri BA, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:156\u201363. e152.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2317_CR39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.23312","volume":"51","author":"VW Wong","year":"2010","unstructured":"Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454\u201362.","journal-title":"Hepatology"},{"key":"2317_CR40","doi-asserted-by":"crossref","unstructured":"Josloff K, Beiriger J, Khan A, Gawel RJ, Kirby RS, Kendrick AD, Rao AK et al. Comprehensive Review of Cardiovascular Disease risk in nonalcoholic fatty liver disease. J Cardiovasc Dev Dis 2022;9.","DOI":"10.3390\/jcdd9120419"},{"key":"2317_CR41","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, Longenecker CT, et al. Global Burden of Atherosclerotic Cardiovascular Disease in people living with HIV: systematic review and Meta-analysis. Circulation. 2018;138:1100\u201312.","journal-title":"Circulation"},{"key":"2317_CR42","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, Loomba R, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559\u201369.","journal-title":"N Engl J Med"},{"key":"2317_CR43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341\u201350.","journal-title":"N Engl J Med"},{"key":"2317_CR44","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1365-2796.2012.02562.x","volume":"272","author":"J Wang","year":"2012","unstructured":"Wang J, Stancakova A, Soininen P, Kangas AJ, Paananen J, Kuusisto J, Ala-Korpela M, et al. Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men. J Intern Med. 2012;272:562\u201372.","journal-title":"J Intern Med"},{"key":"2317_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0009-9120(03)00078-X","volume":"36","author":"S Rashid","year":"2003","unstructured":"Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003;36:421\u20139.","journal-title":"Clin Biochem"},{"key":"2317_CR46","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1042\/bst0311066","volume":"31","author":"CJ Packard","year":"2003","unstructured":"Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans. 2003;31:1066\u20139.","journal-title":"Biochem Soc Trans"},{"key":"2317_CR47","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, Ference BA, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42:4791\u2013806.","journal-title":"Eur Heart J"},{"key":"2317_CR48","doi-asserted-by":"publisher","first-page":"e3275","DOI":"10.1093\/cid\/ciaa1303","volume":"73","author":"M Khalili","year":"2021","unstructured":"Khalili M, King WC, Kleiner DE, Jain MK, Chung RT, Sulkowski M, Lisker-Melman M, et al. Fatty liver disease in a prospective north American cohort of adults with Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. Clin Infect Dis. 2021;73:e3275\u201385.","journal-title":"Clin Infect Dis"},{"key":"2317_CR49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2013.01.022","volume":"227","author":"AP DeFilippis","year":"2013","unstructured":"DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, Blumenthal RS, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2013;227:429\u201336.","journal-title":"Atherosclerosis"},{"key":"2317_CR50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.orcp.2015.01.003","volume":"9","author":"M Iwasa","year":"2015","unstructured":"Iwasa M, Ishihara T, Mifuji-Moroka R, Fujita N, Kobayashi Y, Hasegawa H, Iwata K, et al. Elevation of branched-chain amino acid levels in diabetes and NAFL and changes with antidiabetic drug treatment. Obes Res Clin Pract. 2015;9:293\u20137.","journal-title":"Obes Res Clin Pract"},{"key":"2317_CR51","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00726-014-1894-9","volume":"47","author":"AD Lake","year":"2015","unstructured":"Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, et al. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids. 2015;47:603\u201315.","journal-title":"Amino Acids"},{"key":"2317_CR52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hep.29465","volume":"67","author":"M Gaggini","year":"2018","unstructured":"Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, Ciociaro D, et al. Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance. Hepatology. 2018;67:145\u201358.","journal-title":"Hepatology"},{"key":"2317_CR53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/HMER.S79100","volume":"7","author":"M Kawanaka","year":"2015","unstructured":"Kawanaka M, Nishino K, Oka T, Urata N, Nakamura J, Suehiro M, Kawamoto H, et al. Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease. Hepat Med. 2015;7:29\u201335.","journal-title":"Hepat Med"},{"key":"2317_CR54","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, Overton ET, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV infection. N Engl J Med. 2023;389:687\u201399.","journal-title":"N Engl J Med"},{"key":"2317_CR55","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"2317_CR56","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/apt.17849","volume":"59","author":"S Gawrieh","year":"2024","unstructured":"Gawrieh S, Vilar-Gomez E, Woreta TA, Lake JE, Wilson LA, Price JC, Naggie S, et al. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Aliment Pharmacol Ther. 2024;59:666\u201379.","journal-title":"Aliment Pharmacol Ther"},{"key":"2317_CR57","doi-asserted-by":"crossref","unstructured":"Gawrieh S, Vilar-Gomez E, Wilson LA, Pike F, Kleiner DE, Neuschwander-Tetri BA, Diehl AM et al. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J Hepatol 2024.","DOI":"10.1016\/j.jhep.2024.05.008"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-024-02317-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T13:08:10Z","timestamp":1729170490000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-024-02317-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2317"],"URL":"https:\/\/doi.org\/10.1186\/s12944-024-02317-4","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol had been reviewed and approved by each site\u2019s the Institutional Review Board (Indiana University School of Medicine, Massachusetts General Hospital, and, UTHealth Science Center). Each participant provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Dr. Lin and Dr. Vilar-Gomez declare no conflicts of interest. Dr. Corey serves on the scientific advisory board for Theratechnologies, Novo Nordisk and BMS and has received grant funding from Boehringer-Ingelheim, BMS and Novartis, Dr. Connelly is an employee of and holds stock in Labcorp, Dr. Gupta receives consultancy fees from ViiV Healthcare and Gilead Sciences and unrestricted research grant funding from ViiV Healthcare, Dr. Lake serves as a consultant to CytoDyn and Theratechnologies, and receives research support from Gilead Sciences and Zydus Pharmaceuticals, Dr. Chalasani declares none for this paper. For full disclosure, he has had paid consulting agreements with Madrigal, GSK, Galectin, Zydus, Altimune, Foresite, Ventyx, Merck and Pfizer. He has research grants from DSM and Exact Sciences. He has equity ownership in Avant Sante Therapeutics, a contract research organization., Dr. Gawrieh consulting: TransMedics, Pfizer. Research grant support: Viking and Zydus.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"339"}}